Commercial Supply Solifenacin Succinate Related Intermediates:
Solifenacin Succinate CAS: 242478-38-2
(R)-(-)-3-Quinuclidinol CAS: 25333-42-0
(S)-(+)-3-Quinuclidinol CAS: 34583-34-1
3-Quinuclidinone Hydrochloride CAS: 1193-65-3
1-Phenyl-1,2,3,4-Tetrahydro-Isoquinoline CAS: 22990-19-8
(S)-1-Phenyl-1,2,3,4-Tetrahydroisoquinoline CAS: 118864-75-8
| Chemical Name |
Solifenacin Succinate |
| Synonyms |
Vesicare; 1-Azabicyclo[2.2.2]octan-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate butanedioic acid |
| CAS Number |
242478-38-2 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C23H26N2O2·C4H6O4 |
| Molecular Weight |
480.56 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White or Almost White Crystalline Powder |
| Identification |
By IR; By HPLC |
| Solubility |
Freely Soluble in Acetic Acid, Water, Methanol |
| Melting Point |
144.0~150.0℃ |
| Specific Optical Rotation |
+88.0º~+94.0º |
| Loss on Drying |
≤0.50% |
| Residue on Ignition |
≤0.10% |
| 3-Quinuclidinol |
≤0.20% |
| Succinate Content |
23.5~25.5% |
| Optical Isomer |
|
| Diastereoisomer RS |
≤0.15% |
| Diastereoisomer SS |
≤0.15% |
| Diastereoisomer RR |
≤0.20% |
| Residual Solvents |
|
| Acetone |
≤5000ppm |
| Dichloromethane |
≤600ppm |
| Toulene |
≤890ppm |
| Diisopropyl Ether |
≤500ppm |
| Dimethyl Formamide |
≤880ppm |
| Related Substances |
|
| Any Single Impurity |
≤0.10% |
| Total Impurities |
≤0.50% |
| Heavy Metals |
≤20ppm |
| Purity / Analysis Method |
≥99.5% (HPLC on dried basis) |
| Test Standard |
Enterprise Standard |
| Usage |
API; Overactive Bladder |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.
Solifenacin Succinate (CAS: 242478-38-2) is an antimuscarinic medication that is used to treat an overactive bladder causing symptoms of frequency, urgency, or incontinence. Solifenacin Succinate is an M3 muscarinic receptor antagonist that was developed and launched for the treatment of overactive bladder (pollakiuria) in Europe. M3 receptors have been implicated in neurally evoked smooth muscle contractions of the bladder, and M2 receptors have also been suspected of playing a role because of their dominance in the detrusor muscle. It is used for Urological medicine. Solifenacin Succinate is a urinary antispasmodic of the antimuscarinic class.